Physician profile
Diane Day
NPI 1275991945
$8,819.47
in general payments reported to CMS, 2019-2025
42 companies · $962 in 2025
The $962 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $1,138 · 2021: $1,671 · 2022: $750 · 2023: $1,950 · 2024: $1,293 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,192.20 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,720.17 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,031.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $949.07 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $691.74 | 2019-2025 | |
| Abbvie INC. | $667.51 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.66 | 2019-2024 | Jardiance |
| Amgen INC. | $457.50 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $338.91 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $185.67 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $174.02 | 2023-2024 | Voquezna |
| Eisai INC. | $163.42 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $160.82 | 2019 | |
| Merck Sharp & Dohme LLC | $141.77 | 2019-2024 | Belsomra, Steglatro, Gardasil |
| Limflow INC. | $134.62 | 2023 | Limflow System |
| Glaxosmithkline, LLC. | $133.58 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.